Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy.
Taylor
J C
JC
Orkin
R
R
Lanham
J
J
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure; D014397:Tuberculosis, Pulmonary / Q000150:complications*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D000069285:Infliximab